David Yang

David Yang

Auto-generated profile, based on publicly available information

David Yang

Department of Urology , Mayo Clinic, Rochester, MN 55905, United States

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2020 in International Journal Of Impotence Research
Verified
Journal Article
Closed access
PDF file
KSKiran L. Sharma
Kiran L. Sharma
RBRaevti Bole
Raevti Bole
DYDavid Yang
David Yang
MAManaf Alom
Manaf Alom
JSJoshua Savage
Joshua Savage
LTLandon Trost
Landon Trost

11 January 2023 in The Journal of Sexual Medicine
Verified
Journal Article
Open access
PDF file
RBRaevti Bole
Raevti Bole
EHEngy Habashy
Engy Habashy
DYDavid Yang
David Yang
MMMohamed Ahmed Mbbch
Mohamed Ahmed Mbbch
LTLandon Trost
Landon Trost
TKTobias Kohler
Tobias Kohler
The advent of antibiotic-coated devices has reduced the rate of inflatable penile prosthesis (IPP) infections; however, this may have altered microbial profiles when infections do occur. To describe the timing and causative organisms behind infection of infection retardant–coated IPPs in the context of our institution’s perioperative antimicrobial protocols. We retrospectively reviewed all patients undergoing IPP placement at our institution from January 2014 to January 2022. In all patients, perioperative antibiotic administration was congruent with American Urological Association guidelines. Boston Scientific devices are impregnated with InhibiZone (rifampin and minocycline), and all Coloplast devices were soaked in rifampin and gentamicin. Intraoperative irrigation was performed with betadine 5% irrigation prior to November 2016 and with vancomycin-gentamicin solution afterward. Cases involving prosthesis infection were identified, and variables were extracted from the medical record. Descriptive and comparative statistics were tabulated to identify clinical characteristics, including patient comorbidities, prophylaxis regimen, symptom onset, and intraoperative culture result. We previously reported an increased infection risk with Betadine irrigation and stratified results accordingly. The primary outcome was time to infectious symptoms, while the secondary outcome was description of device cultures at the time of explantation. A total of 1071 patients underwent IPP placement over 8 years with an overall infection rate of 2.6% (28/1071). After discontinuation of Betadine, the overall infection rate was significantly lower at 0.9% (8/919) with a relative risk of 16.9 with Betadine (P < .0001). Primary procedures represented 46.4% (13/28). Of 28 patients with infection, only 1 had no identified risk factors; the remainder included Betadine at 71% (20/28), revision/salvage procedure at 53.6% (15/28), and diabetes at 50% (14/28). Median time to symptoms was 36 days (IQR, 26-52); almost 30% of patients had systemic symptoms. Organisms with high virulence, or ability to cause disease, were found in 90.5% (19/21) of positive cultures. Our study revealed a median time to symptoms of just over 1 month. Risk factors for infection were Betadine 5% irrigation, diabetes, and revision/salvage cases. Over 90% causative organisms were virulent, demonstrating a microbial profile trend since antibiotic coating development. The large prospectively maintained database is a strength along with the ability to follow specific changes in perioperative protocols. The retrospective nature of the study is a limitation as well as the low infection rate, which limits certain subanalyses from being performed. IPP infections present in a delayed manner despite the rising virulence of infecting organisms. These findings highlight areas for improvement in perioperative protocols in the contemporary prosthetics era.

1 December 2019 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
DYDavid Y. Yang
David Y. Yang
IFIgor Frank
Igor Frank
RARoss A. Avant
Ross A. Avant
AMAdam R. Miller
Adam R. Miller
PTPrabin Thapa
Prabin Thapa
MTMatthew K. Tollefson
Matthew K. Tollefson

1 February 2022 in Urology
Verified
Journal Article
Closed access
AMAbrar Mian
Abrar Mian
MPMark Pachorek
Mark Pachorek
ASAndre-Philippe Sam
Andre-Philippe Sam
NRNora H Ruel
Nora H Ruel
DYDavid Yang
David Yang
JWJonathan N. Warner
Jonathan N. Warner

8 December 2020 in Sexual Medicine
Verified
Journal Article
Open access
PDF file
DYDavid Yang
David Yang
JSJoshua Savage
Joshua Savage
TKTobias Köhler
Tobias Köhler
SHSevann Helo
Sevann Helo
LTLandon Trost
Landon Trost
MZMatthew Ziegelmann
Matthew Ziegelmann
Peyronie's disease (PD) is associated with significant psychosocial distress, including anxiety, depression, and negative effects on interpersonal relationships. We report outcomes in a patient who researched an enzymatic supplement intended for oral administration for treatment of PD and subsequently self-injected it intravascularly. The enzyme, a combination of serrapeptase and nattokinase, resulted in vascular necrosis of the upper extremity. Despite attempts to salvage the limb, he ultimately required transhumeral amputation. Although extreme, this case illustrates the potential risks of non–Food and Drug Administration–approved therapies, the significant psychosocial impact that PD can have on patients' emotional well-being, and the extent to which some may go to seek treatment. Yang D, Savage J, Kohler T, et al. Vascular Necrosis of the Upper Extremity After Self-Treatment for Peyronie's Disease. Sex Med 2021;9:100282.

1 March 2021 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
DYD. Yang
D. Yang
MZM. Ziegelmann
M. Ziegelmann
MMM. Manka
M. Manka
JSJ. Savage
J. Savage
SHS. Helo
S. Helo
LTL. Trost
L. Trost
Penile length loss is a common complaint among men with diabetes mellitus (DM). Although robust epidemiological studies are lacking, limited data suggest reductions in all penile dimensions among diabetic men, including a mean 1 cm loss compared to men without DM. Penile traction therapy (PTT) is one treatment often recommended to help restore lost penile length. Recently, a novel PTT device, RestoreX, was developed in cooperation with Mayo Clinic Ventures and demonstrated significant length improvements with 30 minutes daily use.